Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Long-Term Investments (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Long-Term Investments for 7 consecutive years, with $78.6 million as the latest value for Q4 2025.

  • Quarterly Long-Term Investments fell 43.93% to $78.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $78.6 million through Dec 2025, down 43.93% year-over-year, with the annual reading at $78.6 million for FY2025, 43.93% down from the prior year.
  • Long-Term Investments hit $78.6 million in Q4 2025 for Protagonist Therapeutics, down from $102.7 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $140.3 million in Q4 2024 to a low of $2.0 million in Q3 2023.
  • Historically, Long-Term Investments has averaged $69.7 million across 4 years, with a median of $78.6 million in 2025.
  • Biggest five-year swings in Long-Term Investments: surged 5630.0% in 2024 and later tumbled 43.93% in 2025.
  • Year by year, Long-Term Investments stood at $38.2 million in 2021, then plummeted by 94.76% to $2.0 million in 2023, then skyrocketed by 6912.6% to $140.3 million in 2024, then crashed by 43.93% to $78.6 million in 2025.
  • Business Quant data shows Long-Term Investments for PTGX at $78.6 million in Q4 2025, $102.7 million in Q3 2025, and $102.5 million in Q2 2025.